Literature DB >> 2118650

Immunoglobulin heavy-chain-associated amyloidosis.

M Eulitz1, D T Weiss, A Solomon.   

Abstract

Immunoglobulin- or multiple myeloma-associated amyloidosis has been distinguished by the tissue deposition of Congophilic, fibrillar protein consisting of light chains or light-chain fragments (AL amyloidosis). We now report the isolation and characterization of another form of immunoglobulin-associated amyloid obtained from a patient who had extensive systemic amyloidosis and in whom the amyloid deposits consisted not of light chains but rather of an unusual form of heavy chain. This component, isolated from splenic amyloid extracts, represented an internally deleted IgG1 heavy chain as evidenced by immunochemical, electrophoretic, and amino acid sequence analyses. A comparable immunoglobulin-related monoclonal protein, consisting only of IgG heavy chains, was present in the patient's urine. Based on serologic reactivity with a battery of anti-immunoglobulin antisera, these two immunoglobulin-related components were antigenically identical; however, when compared to normal IgG, both were deficient in Fc-associated gamma-chain determinants. The structural abnormality of the amyloid gamma-chain protein was further evidenced by SDS/PAGE and immuno-blotting analyses: An unusually low molecular mass of approximately 22 kDa was found for this material vs. the expected value of approximately 55 kDa for a normal gamma heavy chain. Despite the lack of certain Fc determinants, the amyloid and urinary heavy-chain proteins expressed the IgG1 subclass allotype marker G1m(a) located on the third constant region (CH3) domain of the internally deleted IgG1 heavy chains. That the amyloid protein contained an intact CH3 domain was established through amino acid sequence analyses of cyanogen bromide fragments and peptides generated by a lysine-specific protease. These studies also revealed that the gamma-chain amyloid protein contained the complete heavy-chain variable (VH) domain [including the diversity (DH) and joining (JH) segments] that was contiguous with the CH3 domain. The low molecular mass of the protein resulted from the total absence of the first (CH1), hinge, and second (CH2) heavy-chain constant regions. Such extensive CH deletions and the presence of a complete VH distinguish this amyloid-associated heavy chain from all other heretofore characterized gamma-heavy-chain disease proteins. This heavy-chain-related form of immunoglobulin-associated amyloidosis is tentatively designated AH amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118650      PMCID: PMC54572          DOI: 10.1073/pnas.87.17.6542

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  A new supporting medium for preparative electrophoresis.

Authors:  H J MULLER-EBERHARD
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

Review 2.  Gamma heavy chain disease and rheumatoid arthritis.

Authors:  J R Dickson; M Harth; D A Bell; R Komar; W B Chodirker
Journal:  Semin Arthritis Rheum       Date:  1989-05       Impact factor: 5.532

Review 3.  Human immunoglobulin heavy chain genes.

Authors:  J D Capra; P W Tucker
Journal:  J Biol Chem       Date:  1989-08-05       Impact factor: 5.157

4.  In vitro production of an amyloid-like substance from gamma 3 heavy chain disease protein.

Authors:  W Pruzanski; A Katz; S C Nyburg; M H Freedman
Journal:  Immunol Commun       Date:  1974

Review 5.  Heavy chain diseases: clinical features and molecular significance of the disordered immunoglobulin structure.

Authors:  B Frangione; E C Franklin
Journal:  Semin Hematol       Date:  1973-01       Impact factor: 3.851

6.  The chromatographic determination of cystine and cysteine residues in proteins as s-beta-(4-pyridylethyl)cysteine.

Authors:  M Friedman; L H Krull; J F Cavins
Journal:  J Biol Chem       Date:  1970-08-10       Impact factor: 5.157

7.  Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins.

Authors:  T Isobe; E F Osserman
Journal:  N Engl J Med       Date:  1974-02-28       Impact factor: 91.245

8.  At least five DH genes of human immunoglobulin heavy chains are encoded in 9-kilobase DNA fragments.

Authors:  Y Ichihara; M Abe; H Yasui; H Matsuoka; Y Kurosawa
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

9.  Gamma heavy chain disease in man. Genomic sequence reveals two noncontiguous deletions in a single gene.

Authors:  A Alexander; I Anicito; J Buxbaum
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

10.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

View more
  16 in total

1.  In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.

Authors:  Elena S Klimtchuk; Tatiana B Prokaeva; Brian H Spencer; Olga Gursky; Lawreen H Connors
Journal:  Amyloid       Date:  2017-06-20       Impact factor: 7.141

2.  Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis; Nelson Leung; Angela Dispenzieri; Samih H Nasr; Mary E Fidler; Lynn D Cornell; Jeffrey D Gamez; Julie A Vrana; Ahmet Dogan
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 3.  Current perspectives on cardiac amyloidosis.

Authors:  Jian Guan; Shikha Mishra; Rodney H Falk; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

4.  Transgenic mouse model of AA amyloidosis.

Authors:  A Solomon; D T Weiss; M Schell; R Hrncic; C L Murphy; J Wall; M D McGavin; H J Pan; G W Kabalka; M J Paulus
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 5.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 6.  Deposition-associated diseases related with a monoclonal compound.

Authors:  M J Molina-Garrido; C Guillén-Ponce; A Mora; M Guirado-Risueño; M A Molina; M J Molina; A Carrato
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

7.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

8.  Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum.

Authors:  Vincent Audard; Benoit Georges; Philippe Vanhille; Cécile Toly; Benjamin Deroure; Fadi Fakhouri; René Cuvelier; Xavier Belenfant; Brigitte Surin; Pierre Aucouturier; Béatrice Mougenot; Pierre Ronco
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-16       Impact factor: 8.237

9.  Progressive liver failure in a patient with adult Niemann-Pick disease associated with generalized AL amyloidosis.

Authors:  H Zhou; R P Linke; H E Schaefer; W Möbius; U Pfeifer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases.

Authors:  Virginia Castillo; Salvador Ventura
Journal:  PLoS Comput Biol       Date:  2009-08-21       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.